Breakthrough study reveals Delcath Systems’ therapy doubles survival for uveal melanoma patients

Delcath Systems, Inc. (Nasdaq: DCTH), a pioneering company in interventional oncology, has announced promising results from a recent independent study evaluating its liver-directed therapy for ... Read More